SOT, or Supportive Oligonucleotide Therapy, is an experimental treatment that uses short, custom-made RNA molecules designed to interfere with the genetic activity of viruses, bacteria, or cancer cells. It is offered at integrative and alternative medicine clinics in the United States and Europe, primarily for chronic infections like Lyme disease and Epstein-Barr virus, as well as certain cancers. SOT is not FDA-approved, has no registered clinical trials in the U.S., and the published evidence supporting it remains preliminary and limited.
How SOT Works
The basic concept behind SOT borrows from a well-established area of molecular biology called antisense technology. In simple terms, every virus, bacterium, or cancer cell relies on specific genetic instructions (carried by molecules called mRNA) to survive and replicate. SOT involves creating a short strand of RNA that is complementary to one of those critical instructions. When this custom strand encounters its target, it binds to the mRNA like a lock fitting a key, blocking the pathogen or cancer cell from reading that instruction and carrying out the function it needs to survive.
The molecules used in SOT are sometimes described as small interfering RNAs, or siRNAs. This is the same general class of molecule used in a handful of FDA-approved drugs for other conditions, which is part of why the concept sounds plausible. The difference is that those approved drugs went through years of rigorous clinical trials to establish safe dosing, effectiveness, and delivery methods. SOT has not undergone that process.
What SOT Is Used For
Clinics offering SOT typically market it for two broad categories: chronic infections and cancer.
On the infection side, the most commonly targeted conditions include Lyme disease (caused by the bacterium Borrelia burgdorferi), Epstein-Barr virus (EBV), and herpes simplex viruses 1 and 2 (HSV-1/HSV-2). One preliminary study published in a peer-reviewed journal evaluated 115 patients across these three conditions: 59 with EBV, 28 with HSV-1 or HSV-2, and 28 with Lyme disease. The study described SOT as a “potential” treatment and characterized its own results as preliminary.
For cancer, clinics claim that SOT can target circulating tumor cells found in the patient’s blood. The idea is that by analyzing those cells in a lab, scientists can identify a genetic vulnerability specific to the patient’s cancer and design an RNA molecule to exploit it. A separate preliminary study described this process but did not provide large-scale efficacy data.
The Treatment Process
SOT is a personalized treatment, meaning each dose is manufactured for an individual patient. The process starts with a blood draw, typically 15 to 30 milliliters (roughly one to two tablespoons). That blood sample is shipped to a specialized laboratory, most commonly RGCC, a company based in Greece that manufactures SOT molecules.
For cancer applications, the lab isolates circulating tumor cells from the blood sample using a multi-step process involving centrifuging, filtering, and tagging the cells with specific protein markers. The lab then tests which RNA sequences are effective against those particular cells. For infections, the lab identifies RNA sequences that target genetic material essential to the pathogen in question.
Once the custom molecules are manufactured, they are shipped back to the ordering clinic. The patient receives SOT as a single intravenous infusion. The solution is reconstituted in a small volume of sterile water (about 10 milliliters total) and administered through an IV. Patients also receive a steroid medication intravenously beforehand to help stabilize the veins and reduce the chance of the solution leaking out of the bloodstream during the infusion.
What the Evidence Actually Shows
The published research on SOT is extremely limited. As of early 2024, only a small number of preliminary studies have appeared in peer-reviewed journals, and none of them are the kind of large, controlled trials that the medical community relies on to confirm whether a treatment works. The studies that do exist were conducted by researchers affiliated with RGCC, the same company that manufactures and sells SOT, which raises questions about independence.
No results appear on ClinicalTrials.gov, the U.S. government’s registry of clinical studies, for either “SOT” or “supportive oligonucleotide therapy.” This means there are no registered, ongoing clinical trials testing SOT in a structured way with proper controls. For a treatment being marketed for serious conditions like cancer and Lyme disease, the absence of controlled trial data is a significant gap. Without randomized trials comparing SOT to a placebo or standard treatment, it is impossible to know whether any improvements patients experience are caused by the therapy itself or by other factors.
FDA Status and Regulatory Concerns
SOT is not approved by the FDA. It does not have an Investigational New Drug (IND) application on file, which is the standard pathway that allows an experimental therapy to be tested in U.S. clinical trials. Because SOT is marketed to treat serious medical conditions like cancer and Lyme disease, it would likely be classified as a drug under U.S. law, meaning it should require pre-market FDA approval before being sold to patients.
Despite this, dozens of integrative medicine clinics across the United States currently offer SOT. The treatment exists in a regulatory gray area that is common in the alternative medicine space, where therapies are sometimes framed as personalized or supportive rather than as drugs, allowing them to operate outside traditional regulatory oversight. Paul Knoepfler, a stem cell biologist at UC Davis who has investigated SOT marketing in the U.S., has noted that clinics are “widely selling” the therapy without the kind of evidence base that would normally be required.
Cost and Insurance Coverage
SOT is expensive. A single treatment typically costs several thousand dollars, and many clinics recommend repeat infusions over time. Because the therapy is not FDA-approved and lacks clinical trial support, health insurance plans do not cover it. The entire cost falls on the patient, and there is no guarantee of a clinical benefit. Patients should also factor in the cost of follow-up blood work that clinics often recommend to monitor the treatment’s effects.
What to Weigh Before Considering SOT
The underlying science of antisense RNA technology is real and has produced legitimate, FDA-approved therapies for other conditions. That scientific plausibility is part of what makes SOT appealing to patients who are struggling with chronic illness and looking for options beyond conventional treatment. However, plausibility is not the same as proof. Many treatments that seemed promising in early-stage research failed to show benefit, or even caused harm, when tested in rigorous trials.
The key concerns with SOT are the lack of controlled clinical trial data, the absence of FDA oversight, the high out-of-pocket cost, and the fact that nearly all published research comes from the company that profits from the therapy. For patients with serious conditions like cancer, choosing an unproven alternative treatment can also mean delaying therapies that have strong evidence behind them, which carries its own risks.